Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease

Circulation

Volumn 121, Issue 19, 2010, Pages 2130-2136

  Antonini Canterin, Francesco ^a   Moura, Luis M ^b   Enache, Roxana ^a   Leiballi, Elisa ^a   Pavan, Daniela ^a   Piazza, Rita ^a   Popescu, Bogdan A ^c   Ginghinǎ, Carmen ^c   Nicolosi, Gian Luigi ^a   Rajamannan, Nalini M ^d  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^b HOSPITAL PEDRO HISPANO   (Portugal)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Mitral valve; Rheumatic heart disease; Statins; Stenosis

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ECHOCARDIOGRAPHY; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MITRAL VALVE DISEASE; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; RHEUMATIC DISEASE;

AGED; AORTIC VALVE INSUFFICIENCY; DATABASES, FACTUAL; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MITRAL VALVE STENOSIS; MULTIVARIATE ANALYSIS; PULMONARY WEDGE PRESSURE; RHEUMATIC HEART DISEASE; TREATMENT OUTCOME;

EID: 77953125275     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.891598     Document Type: Article

References (48)

1. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet. 2005;366:155-168.
2. Rheumatic Fever and Rheumatic Heart Disease: Report of WHO Expert Consultation, Geneva, 29 October-1 November 2001. Geneva, Switzerland: World Health Organization; 2004. Technical Report Series 923.
3. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28:230-268.
4. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003;107:2181-2184.
5. Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation. 2001; 103:1522-1528.
6. Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev CI, Sebo TJ, Rosengart TK, Edwards WD, McCarthy PM, Bonow RO, Spelsberg TC. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation. 2005;111:3296-3301.
7. Chiu-Braga YY, Hayashi SY, Schafranski M, Messias-Reason IJ. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein. Int J Cardiol. 2006;109:275-276.
8. Gölbasi Z, Uçar O, Keles T, Sahin A, Cagli K, Camsari A, Diker E, Aydogdu S. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease evidence of ongoing inflammation. Eur J Heart Fail. 2002;4:593-595.
9. Krasuski RA, Bush A, Kay JE, Mayes CE Jr, Wang A, Fleming J, Pierce C, Kisslo KB, Harrison JK, Bashore TM. C-reactive protein elevation independently influences the procedural success of percutaneous balloon mitral valve commissurotomy. Am Heart J. 2003;146:1099-1104.
10. Guilherme L, Cury P, Demarchi LMF, Coelho V, Abel L, Lopez AP, Oshiro SE, Aliotti S, Cunha-Neto E, Pomerantzeff PMA, Tanaka AC, Kalil J. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol. 2004;165:1583-1591.
11. Yetkin E, Erbay AR, Ileri M, Turhan H, Balci M, Cehreli S, Yetkin G, Demirkan D. Levels of circulating adhesion molecules in rheumatic mitral stenosis. Am J Cardiol. 2001;88:1209-1211.
12. Alyan O, Metin F, Kacmaz F, Ozdemir O, Maden O, Topaloglu S, Demir AD, Karahan Z, Karadede A, Ilkay E. High levels of high sensitivity C-reactive protein predict the progression of chronic rheumatic mitral stenosis. J Thromb Thrombolysis. 2009;28:63-69.
13. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693-695. (Pubitemid 32831111)
14. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002;40:1723-1730.
15. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205-2209.
16. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004; 110:1291-1295.
17. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Goncalves F, Rajamannan NM. Rosuvastatin affecting aortic valve en-dothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554-561.
18. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397.
19. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf K, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjærpe T, Wachtell K, Willenheimer R; for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1-14.
20. Antonini-Canterin F, Hirsu M, Popescu BA, Leiballi E, Piazza R, Pavan D, Ginghina? C, Nicolosi GL. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis: a long-term follow-up study in 1046 patients. Am J Cardiol. 2008;102:738-742.
21. Antonini-Canterin F, Leiballi E, Enache R, Popescu BA, Roçsca M, Cervesato E, Piazza R, Ginghina? C, Nicolosi GL. Hydroxymethylglutaryl coenzyme-A reductase inhibitors delay the progression of rheumatic aortic valve stenosis: a long-term echocardiographic study. J Am Coll Cardiol. 2009;53:1874-1879.
22. Otto CM. Textbook of Clinical Echocardiography. 4th ed. Philadelphia, Pa: Saunders Elsevier; 2009:277.
23. Hatle L, Angelsen B, Tromsdal A. Noninvasive assessment of atrioven-tricular pressure half-time by Doppler ultrasound. Circulation. 1979;60: 1096-1104.
24. Henry WL, Griffith JM, Michaelis LL, McIntosh CL, Morrow AG, Epstein SE. Measurement of mitral valve orifice area in patients with mitral valve disease by real-time, two-dimensional echocardiography. Circulation. 1975;51:827-836.
25. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15:167-184.
26. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardio-graphic variables related to outcome and the mechanism of dilatation. Br Heart J. 1988;60:299-308.
27. Dall'Aglio V, D'Angelo G, Moro E, Nicolosi GL, Burelli C, Zardo F, Cervesato E, Zanuttini D. Interobserver and echo-angio variability of two-dimensional colour Doppler evaluation of aortic and mitral regurgi-tation. Eur Heart J. 1989;10:334-340.
28. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
29. Marijon E, Ou P, Celermajer DS, Ferriera B, Mocumbi AO, Jani D, Parquet C, Jacob S, Sidi D, Jouven X. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med. 2007; 357:470-476.
30. Carabello BA. Modern management of mitral stenosis. Circulation. 2005; 112:432-437.
31. Sagie A, Freitas N, Padial LR, Leavitt M, Morris E, Weyman AE, Levine RA. Doppler echocardiographic assessment of long-term progression of mitral stenosis in 103 patients: valve area and right heart disease. J Am Coll Cardiol. 1996;28:472-479.
32. Faletra F, De Chiara F, Crivellaro W, Mantero A, Corno R, Brusoni B. Echocardiographic follow-up in patients with mild to moderate mitral stenosis: is a yearly examination justified? Am J Cardiol. 1996;78: 1450-1452.
33. Gordon SPF, Douglas PS, Come PC, Manning WJ. Two-dimensional and Doppler echocardiographic determinants of the natural history of mitral valve narrowing in patients with rheumatic mitral stenosis: implications for follow-up. J Am Col Cardiol. 1992;19:968-973.
34. Steiner I, Kas?parová P, Kohout A, Dominik J. Bone formation in cardiac valves: a histopathological study of 128 cases. Virchows Arch. 2007;450: 653-657.
35. Osman L, Yacoub MH, Latif N, Amrani M, Chester AH. Role of human valve interstitial cells in valve calcification and their response to atorva-statin. Circulation. 2006;114:I547-I552.
36. Osman L, Chester AH, Amrani M, Yacoub MH, Smolenski RT. A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin. Circulation. 2006;114:I566-I572.
37. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T, Hanafusa T. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholester-olemic rabbits. J Am Coll Cardiol. 2007;49:1482-1489.
38. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, McConnell JP, Singh RJ, Bonow RO, Spelsberg TC. Ator-vastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart. 2005;91:806-810.
39. Makkena B, Salti H, Subramaniam M, Thennapan S, Bonow RH, Caira F, Bonow RO, Spelsberg TC, Rajamannan NM. Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholester-olemic mitral valve. J Am Coll Cardiol. 2005;45:631-633.
40. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorva-statin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002;105: 2660-2665.
41. Davidson MH. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation. 2005;111:2280-2281.
42. Davignon J, Leiter LA. Ongoing clinical trial of the pleiotropic effects of statins. Vasc Health Risk Manag. 2005;I:29-40.
43. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effects of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103: 1933-1935.
44. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009;119:131-138.
45. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation. 2005;112: I229-I234.
46. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707-1712.
47. Ben-Yehuda O, DeMaria AN. Statins in rheumatic heart disease: taking the bite out? J Am Coll Cardol. 2009;53:1880-1882.
48. Rajamannan NM, Antonini-Canterin F, Moura L, Zamorano JL, Rosenhek RA, Best PJM, Lloyd MA, Rocha-Gonçalves F, Chandra S, Alfieri O, Lancellotti P, Tornos P, Baliga RR, Wang A, Bashore T, Ramakrishnan S, Spargias K, Shuvy M, Beeri R, Lotan C, Al Suwaidi J, Bahl V, Pierard LA, Maurer G, Nicolosi GL, Rahimtoola SH, Chopra HK, Pandian NG. Medical therapy for rheumatic heart disease: is it time to be proactive rather than reactive? Indian Heart J. 2009;61:14-23.